CLAIMS

1. Use of a classical complement pathway inhibitor in the manufacture of a medicament for inhibiting refractoriness to platelets in an alloimmunized subject, wherein said platelets have been treated with said classical complement pathway inhibitor; and the treated platelets are to be transfused to the subject; wherein the complement pathway inhibitor is a PIC1 peptide comprising an amino acid sequence of any one of SEQ ID Nos: 1-28 and 30-45.

2. Use of a classical complement pathway inhibitor in the manufacture of a medicament for preventing platelet refractoriness in a subject receiving platelets from an antigenically mismatched donor, wherein the classical complement pathway inhibitor is to be administered to the subject before the platelets are to be transfused to the subject; wherein the complement pathway inhibitor is a PIC1 peptide comprising an amino acid sequence of any one of SEQ ID Nos: 1-28 and 30-45.

3. Use of a classical complement pathway inhibitor in the manufacture of a medicament for preventing platelet refractoriness in a subject receiving platelets from an antigenically mismatched donor, wherein the platelets are treated with said classical complement pathway inhibitor and wherein said treated platelets are to be transfused to the subject; wherein the complement pathway inhibitor is a PIC1 peptide comprising an amino acid sequence of any one of SEQ ID Nos: 1-28 and 30-45.

4. The use of any one of claims 1 to 3, wherein the use is effective to increase survival of the transfused platelets in the subject.

5. The use of any one of claims 1 to 4, wherein the use is effective to reduce complement-mediated attack of the transfused platelets in the subject.

6. The use of any one of claims 1 to 5, wherein the use is effective to increase survival of the transfused platelets in the subject.

7. The use of any one of claims 1 to 6, wherein the subject is human.

8. The use of any one of claims 1-7, wherein the PIC1 peptide comprises an amino acid sequence of any one of SEQ ID NOS: 3, 4, 5, 6, 9, 10, and 19.

9. The use of claim 8, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 3.

10. The use of claim 8, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 4.

11. The use of claim 8, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 5.

12. The use of claim 8, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 6.

13. The use of claim 8, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 9.

14. The use of claim 8, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 10.

15 The use of claim 8, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 19.

16. Use of a classical complement pathway inhibitor in the manufacture of a medicament for treating delayed hemolytic transfusion reaction (DHTR) in a subject wherein a therapeutically effective amount of the classical complement pathway inhibitor is to be

administered to the subject, wherein the complement pathway inhibitor is a PIC1 peptide comprising an amino acid sequence of any one of SEQ ID Nos: 1-28 and 30-45.

17. The use of claim 16, wherein the classical complement pathway inhibitor is to be administered parenterally.

18. The use of claim 16 or claim 17, wherein the subject is human.

19. The use of any one of claim 16 to 18, wherein the PIC1 peptide comprises an amino acid sequence of any one of SEQ ID NOS: 3, 4, 5, 6, 9, 10, and 19.

20. The use of claim 19, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 3.

21. The use of claim 19, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 4.

22. The use of claim 19, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 5.

23. The use of claim 19, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 6.

24. The use of claim 19, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 9.

25. The use of claim 19, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 10.

26. The use of claim 19, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 19.